Cáncer de pulmón y EPOC: una asociación frecuente

Arca, José Abal; Lamelas, Isaura Parente; Ortega, Raquel; Pérez, José Jesús Blanco; Navarro, María Elena; Velázquez, Pedro Marcos

doi:10.1016/j.arbres.2009.07.005

Cited by 26 publications

(13 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of COPD in our study is consistent with some previous results, but slightly lower than others [12, 13, 34]. Even so, we found high rates of underdiagnosis (71.6%), consistent with the available data from other series [34-37].…”

Section: Discussionsupporting

confidence: 83%

Chronic Obstructive Pulmonary Disease in Lung Cancer Patients: Prevalence, Underdiagnosis, and Clinical Characterization

et al. 2018

View full text Add to dashboard Cite

Background: Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) are associated with increased morbidity and mortality. The differential clinical and functional features among LC patients with or without COPD have not been defined. Objectives: The aims of this study were to examine the prevalence and underdiagnosis rate of COPD in LC patients and to compare the clinical and functional features of LC patients with and without COPD. Methods: We designed a multicenter hospital-based study including all LC cases diagnosed from January 2014 to August 2016. We assessed epidemiological, clinical, radiological, functional, and histological variables in all cases. Results: We recruited 602 patients with LC, most of them men (77.9%), with a median age of 67 ± 15 years. The COPD prevalence among LC patients was 51.5%, with a underdiagnosis rate of 71.6%. The LC+COPD patients were older and the proportion of men was higher compared with the LC-only patients. The LC+COPD patients had more pack-years, more squamous LC, a lower monoxide transfer coefficient (KCO), and higher Charlson index scores than patients with LC only. The median survival of LC-only patients was 37% longer than that of LC+COPD patients (22 vs. 16 months), but this difference was not statistically significant. Conclusions: Among LC patients, COPD is prevalent and underdiagnosed. Patients with LC+COPD more often have squamous LC, have greater comorbidities, and have a lower KCO. More effort should be made for an early diagnosis of COPD to select patients at higher risk of developing LC.

show abstract

Section: Discussionsupporting

confidence: 83%

Chronic Obstructive Pulmonary Disease in Lung Cancer Patients: Prevalence, Underdiagnosis, and Clinical Characterization

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Izquierdo et al [12] have also demonstrated similar OS in concomitant COPD and non-COPD NSCLC patients, but in this study again mean age of the former group was 70 vs 66 years in the latter (p < 0.001). Arca et al [13] have confirmed a prolongation of OS among COPD+NSCLC (n = 396) vs only NSCLC patients (n = 600) though the former group was older again by 3.5 years. These authors concluded that COPD increases OS of advanced lung cancer patients, but did not raise any hypothesis for explanation.…”

Section: Discussionmentioning

confidence: 92%

“…Hogg et al [39] have established important roles of CD4 and CD8 T cells in the process connecting heavy smoking with development of COPD. Smoking also increases the risk of lung cancer [13], and many lung cancer patients at the time of diagnosis have already suffered for years from COPD [15]. It has been deeply investigated how various elements of the pathogenesis of COPD contributed to pathogenesis of lung cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Although advanced NSCLC is the cancer of heavy smokers and the elderly most of whom suffer from comorbidities [9], there has been a lack of information how comorbidities influence PFS during and after first-line treatment. The influence of a very frequent comorbidity, chronic obstructive pulmonary disease (COPD) has been studied in only a few previous series [10][11][12][13][14]. PFS [10] and OS [11,12] remained unchanged by COPD after first-line treatment, while in two other studies PFS was observed to become prolonged by concomitant COPD in advanced NSCLC [13,14].…”

Section: Introductionmentioning

confidence: 99%

“…The influence of a very frequent comorbidity, chronic obstructive pulmonary disease (COPD) has been studied in only a few previous series [10][11][12][13][14]. PFS [10] and OS [11,12] remained unchanged by COPD after first-line treatment, while in two other studies PFS was observed to become prolonged by concomitant COPD in advanced NSCLC [13,14]. Mark et al [14] reported that in advanced NSCLC, the presence of COPD was associated with enhanced efficacy of immune checkpoint inhibitors as PFS was longer (p = 0.0168) in NSCLC with COPD versus no COPD (n = 125).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of COPD on Inflammation, Lymphoid Functions and Progression-Free Survival during First-Line Chemotherapy in Advanced Non-small Cell Lung Cancer

Szentkereszty

Komlósi

Szűcs

et al. 2019

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a common comorbidity of non-small cell lung cancer (NSCLC). COPD is characterized by systemic inflammation and lymphocyte dysfunction, mechanisms that are also known to accelerate progression of advanced (IIIB-IV) stage NSCLC. We aimed to find out whether COPD exerts an influence on tumor induced inflammatory and lymphoid responses and progression-free survival (PFS) after first-line treatment in advanced NSCLC. Patients suffering from NSCLC (n = 95), COPD (n = 54), NSCLC+COPD (n = 80) and healthy controls (n = 60) were included. PFS, neutrophil granulocyte and lymphocyte cell counts were recorded. Serum IFNγ, TNFα, VEGF concentrations were measured by using multiplex cytometric bead-based immunoassay. Prevalence of myeloid-derived suppressor cell populations (MDSC-s), and signs of T cell exhaustion were tested by using flow cytometry. Median PFS increased in the NSCLC+COPD group compared to NSCLC patients without COPD (7.4 vs 4.9 months, p < 0.01). NSCLC+COPD patients had 1.7 times (1.2-2.4) more likely to have longer PFS compared to NSCLC patients without COPD (Cox analysis, p < 0.01). Neutrophil cell counts, CRP, IFNγ and TNFα concentrations were all reduced in NSCLC+COPD (all p < 0.05 vs NSCLC). NSCLC+COPD was also associated with reduced serum IL-10 concentration and increased granzyme-B positive CD8 cell counts compared to NSCLC without COPD. The effects of VEGF and MDSC-s on systemic inflammation appeared to be blunted by COPD in patients suffering from advanced NSCLC. Concomitant COPD moderates tumor-induced inflammation and supports some effector lymphoid functions and thereby may be an independent positive predictive factor of longer PFS after first-line therapy in advanced NSCLC.

show abstract

Intervenciones en tabaquismo en pacientes con enfermedades cardiovasculares

Granda‐Orive¹,

Solano-Reina²,

Jiménez-Ruíz³

2013

Atención Primaria

View full text Add to dashboard Cite

Smoking tobacco is the main cardiovascular risk factor and has a dose-dependent response. It has been shown that an aggressive policy, not only against consumption, achieves a significant decrease in cardiovascular deaths. Thus, we must provide and carry out activities to prevent or decrease the incidence of smoking (primary prevention), and to the early detection of the smoker and to reduce the prevalence (secondary prevention), and lastly to act on the effects of tobacco smoke, preventing complication and remissions (tertiary prevention). Thus, all health care levels must act in order that smokers do not develop cardiovascular disease when they quit smoking, both from Primary, as well as specialist care.

show abstract

Cáncer de pulmón y EPOC: una asociación frecuente

Cited by 26 publications

References 37 publications

Chronic Obstructive Pulmonary Disease in Lung Cancer Patients: Prevalence, Underdiagnosis, and Clinical Characterization

Chronic Obstructive Pulmonary Disease in Lung Cancer Patients: Prevalence, Underdiagnosis, and Clinical Characterization

Effect of COPD on Inflammation, Lymphoid Functions and Progression-Free Survival during First-Line Chemotherapy in Advanced Non-small Cell Lung Cancer

Intervenciones en tabaquismo en pacientes con enfermedades cardiovasculares

Contact Info

Product

Resources

About